SCHEMBL5363593

SCHEMBL5363593

CC(=O)Nc1ccc2c(C)cc(O)nc2n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
XIAP P98170 1/20 0.52
ADORA3 P0DMS8 4/20 0.41
ADORA1 P30542 2/20 0.41
KDM4E B2RXH2 3/20 0.40
LMNA P02545 1/20 0.40
ADORA2B P29275 1/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
HSP90AA1 P07900 1/20 0.39
HSP90AB1 P08238 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA9 Q16790 1/20 0.38
MAPK13 O15264 1/20 0.38
MAPK12 P53778 1/20 0.38
MAPK11 Q15759 1/20 0.38
MAPK14 Q16539 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11491259 0.86 XIAP (0.68) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL5365213 0.84 XIAP (0.51) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL23925233 0.80 GAA (0.47) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL9378955 0.80 KDM4E (0.38) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL9381323 0.80 XIAP (0.41) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL11591216 0.79 ADORA1 (0.51) ADORA3ADORA1KDM4ELMNAADORA2B
SCHEMBL11486868 0.77 XIAP (0.44) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL17407740 0.76 KMT2A (0.43) XIAPKDM4ELMNAMAOBCA12
SCHEMBL9381376 0.72 MAPK8 (0.40) XIAPADORA3ADORA1KDM4ELMNA
SCHEMBL6435049 0.71 KDM4E (0.43) ADORA3ADORA1KDM4ELMNAADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7160888-B2 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER LAMBERT COMPANY LLC (US) 2007-01-09 US disclosed
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
EP-1660497-A1 [ 1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2006-05-31 EP disclosed
WO-2005019215-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2005-03-03 WO disclosed
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2005-02-24 US disclosed
US-4202981-A Substituted -6,7,8,9-tetrahydro-pyrido- and 2H-pyrano [2,3-b][1,8]naphthyridines, stable efficient laser dyes THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1980-05-13 US disclosed
US-4103257-A BLUE TO NEAR ULTRAVIOLET THE UNITED STATES OF AMERICA AS REPRESENTED BY THE UNITED STATES DEPARTMENT OF ENERGY (US) 1978-07-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043309-A1 [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia DRD1, DRD2, DRD3 XIAP 3652/4885ADORA3 910/4885ADORA1 485/4885
US-20060287309-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 XIAP 3652/4885ADORA3 910/4885ADORA1 485/4885
US-20060287310-A1 [1,8]NAPHTHYRIDIN-2-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA DRD1, DRD2, DRD3 XIAP 3652/4885ADORA3 910/4885ADORA1 485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.